Evidence map›Paper›PMID 23497229›Full record

ArticleMalaria journal2013

Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan.

Ghulam R Awab, Sasithon Pukrittayakamee, Natsuda Jamornthanyawat, Fazel Yamin, Arjen M Dondorp, Nicholas Pj Day, Nicholas J White, Charles J Woodrow, Mallika Imwong

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Epidemiology and Control of Plasmodium vivax in Afghanistan.The American journal of tropical medicine and hygiene · 2016
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Ghulam R AwabMahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Bangkok, Thailand.
Sasithon Pukrittayakamee
Natsuda Jamornthanyawat
Fazel Yamin
Arjen M Dondorp
Nicholas Pj Day
Nicholas J White
Charles J Woodrow
Mallika Imwong
Mahidol Oxford Tropical Medicine Research Unit · THChurchill Hospital · GBMinistry of Public Health · AFUniversity of Oxford · GB

Funding

Wellcome Trust 089275Wellcome Trust 093956
6 · The paper itself

Abstract

backgroundArtesunate plus sulphadoxine-pyrimethamine (AS+SP) is now first-line treatment for Plasmodium falciparum infection in several south Asian countries, including Afghanistan. Molecular studies provide a sensitive means to investigate the current state of drug susceptibility to the SP component, and can also provide information on the likely efficacy of other potential forms of artemisinin-combination therapy.

methodsDuring the years 2007 to 2010, 120 blood spots from patients with P. falciparum malaria were obtained in four provinces of Afghanistan. PCR-based methods were used to detect drug-resistance mutations in dhfr, dhps, pfcrt and pfmdr1, as well as to determine copy number of pfmdr1.

resultsThe majority (95.5%) of infections had a double mutation in the dhfr gene (C59R, S108N); no mutations at dhfr positions 16, 51 or 164 were seen. Most isolates were wild type across the dhps gene, but five isolates from the provinces of Kunar and Nangarhar in eastern Afghanistan had the triple mutation A437G / K540E / A581G; all five cases were successfully treated with three receiving AS+SP and two receiving dihydroartemisinin-piperaquine. All isolates showed the pfcrt SVNMT chloroquine resistance haplotype. Five of 79 isolates had the pfmdr1 N86Y mutation, while 52 had pfmdr1 Y184F; positions 1034, 1042 and 1246 were wild type in all isolates. The pfmdr1 gene was not amplified in any sample.

conclusionsThis study indicates that shortly after the adoption of AS+SP as first-line treatment in Afghanistan, most parasites had a double mutation haplotype in dhfr, and a small number of isolates from eastern Afghanistan harboured a triple mutation haplotype in dhps. The impact of these mutations on the efficacy of AS+SP remains to be assessed in significant numbers of patients, but these results are clearly concerning since they suggest a higher degree of SP resistance than previously detected. Further focused molecular and clinical studies in this region are urgently required.

Indexed as

Drug ResistanceMutation, MissenseAdultAfghanistanAntimalarialsArtemisininsArtesunateChildChild, PreschoolDNA, ProtozoanDrug CombinationsFolic Acid AntagonistsHumansMalaria, FalciparumPlasmodium falciparumPolymerase Chain ReactionAntimalarialsArtemisininsArtesunateDNA, ProtozoanDrug Combinationsfanasil, pyrimethamine drug combinationFolic Acid AntagonistsProtozoan ProteinsPyrimethamineSulfadoxine

Identifiers

PMID23497229
PMCPMC3607912
OpenAlexW2140054156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.